KDA
- Current
- Browse
- Collections
-
For contributors
- For Authors
- Instructions to authors
- Article processing charge
- e-submission
- For Reviewers
- Instructions for reviewers
- How to become a reviewer
- Best reviewers
- For Readers
- Readership
- Subscription
- Permission guidelines
- About
- Editorial policy
Search
- Page Path
- HOME > Search
Review
- Lifestyle
- Type 2 Diabetes Mellitus and Sarcopenia as Comorbid Chronic Diseases in Older Adults: Established and Emerging Treatments and Therapies
- Jakub Mesinovic, Jackson J. Fyfe, Jason Talevski, Michael J. Wheeler, Gloria K.W. Leung, Elena S. George, Melkamu T. Hunegnaw, Costas Glavas, Paul Jansons, Robin M. Daly, David Scott
- Diabetes Metab J. 2023;47(6):719-742. Published online September 14, 2023
- DOI: https://doi.org/10.4093/dmj.2023.0112
- 4,917 View
- 452 Download
- 1 Web of Science
- 2 Crossref
-
Abstract
PDF
PubReader 
ePub - Type 2 diabetes mellitus (T2DM) and sarcopenia (low skeletal muscle mass and function) share a bidirectional relationship. The prevalence of these diseases increases with age and they share common risk factors. Skeletal muscle fat infiltration, commonly referred to as myosteatosis, may be a major contributor to both T2DM and sarcopenia in older adults via independent effects on insulin resistance and muscle health. Many strategies to manage T2DM result in energy restriction and subsequent weight loss, and this can lead to significant declines in muscle mass in the absence of resistance exercise, which is also a first-line treatment for sarcopenia. In this review, we highlight recent evidence on established treatments and emerging therapies targeting weight loss and muscle mass and function improvements in older adults with, or at risk of, T2DM and/or sarcopenia. This includes dietary, physical activity and exercise interventions, new generation incretin-based agonists and myostatin-based antagonists, and endoscopic bariatric therapies. We also highlight how digital health technologies and health literacy interventions can increase uptake of, and adherence to, established and emerging treatments and therapies in older adults with T2DM and/or sarcopenia.
-
Citations
Citations to this article as recorded by
- Fucoidan ameliorates diabetic skeletal muscle atrophy through PI3K/Akt pathway
Caixia Li, Yaping Liu, Mingzhi Yang, Haoyue Huang, Lulu Tang, Yufan Miao, Wenjie Li, Xing Li
Journal of Functional Foods.2024; 114: 106076. CrossRef - Evaluation of the effect of testosterone replacement therapy with a transdermal testosterone on glycemic control in men with type 2 diabetes mellitus
R. V. Rozhivanov, M. O. Chernova, V. A. Ioutsi, G. A. Mel’nichenko, M. V. Shestakova, E. R. Rozhivanova, E. N. Andreeva, N. G. Mokrysheva
Diabetes mellitus.2024; 27(2): 120. CrossRef
- Fucoidan ameliorates diabetic skeletal muscle atrophy through PI3K/Akt pathway
First
Prev
